SLC5A2 and infectious otitis media: Studies that featured these AOMs in head-to-head comparisons with non–FDA-approved AOM (including comparisons to oral formulations of approved GLP-1RAs) or other glucose-lowering agents, or medications such as sodium-glucose cotransporter-2 medications, were also included.